PMID- 34078046
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20220531
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 50
IP  - 6
DP  - 2021 Jun 8
TI  - [Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative 
      anaplastic large cell lymphoma].
PG  - 598-603
LID - 10.3760/cma.j.cn112151-20201223-00953 [doi]
AB  - Objective: To investigate the genetic abnormality and protein expression of C-MYC 
      and PD-L1 in the patients with ALK-negative anaplastic large cell lymphoma 
      (ALK(－)ALCL), and to explore their roles in the pathogenesis of ALK(－)ALCL and 
      their relationship with clinicopathological characteristics. Methods: 
      Thirty-seven cases of ALK(－)ALCL diagnosed at Fujian Provincial Hospital from 
      January 2003 to January 2017 were selected. Fluorescence in situ hybridization 
      (FISH) was used to detect the genetic abnormality of C-MYC and PD-L1. The 
      expression of C-MYC and PD-L1 proteins was detected by immunohistochemistry. The 
      relationship between C-MYC and PD-L1 genes' abnormalities and protein expression 
      was analyzed, as well as their associations with various clinicopathological 
      parameters. Results: Among the 37 ALK(－)ALCL patients, 17 (45.9%) were positive 
      for C-MYC protein, and 14 (37.8%) were positive for PD-L1 protein. There was a 
      significant correlation between C-MYC protein and PD-L1 protein 
      (r=0.990,P=0.014). The protein expression of C-MYC and PD-L1 (versus negative) 
      was associated with the clinical stage of ALK(－)ALCL, respectively. The 
      international prognosis index (IPI) in high-risk group was higher than that in 
      the low-risk group (P<0.05). FISH test showed that 9 (24.3%) of the 37 cases had 
      amplification of C-MYC gene, and no translocation of C-MYC gene was found in any 
      of the cases. Amplification of PD-L1 gene was found in only 2 cases (5.4%). The 
      3-year overall survival rate of the C-MYC or PD-L1 immunohistochemistry-positive 
      cases was significantly lower than those of the C-MYC or PD-L1 negative cases 
      (P<0.01 and P<0.05), respectively. Conclusion: The expression of C-MYC and PD-L1 
      proteins are related to the clinical stage, IPI and overall survival rate of 
      ALK(－)ALCL. Thus, it can be used to assess the disease's aggressiveness and to 
      predict the prognosis of ALK(－)ALCL. The expression of PD-L1 in ALK(－)ALCL may be 
      regulated by C-MYC, thus suggesting a possible design of combined C-MYC targeted 
      therapy and immune checkpoint blocking for some ALK(－)ALCL patients.
FAU - Wang, C
AU  - Wang C
AD  - Department of Pathology, Fujian Provincial Hospital, Fujian Provincial; Clinical 
      College of Fujian Medical University, Fuzhou 350001, China.
FAU - Chen, X
AU  - Chen X
AD  - Department of Pathology, Fujian Provincial Hospital, Fujian Provincial; Clinical 
      College of Fujian Medical University, Fuzhou 350001, China.
FAU - Chen, X Y
AU  - Chen XY
AD  - Department of Pathology, Fujian Provincial Hospital, Fujian Provincial; Clinical 
      College of Fujian Medical University, Fuzhou 350001, China.
FAU - You, Z J
AU  - You ZJ
AD  - Department of Pathology, Fujian Provincial Hospital, Fujian Provincial; Clinical 
      College of Fujian Medical University, Fuzhou 350001, China.
LA  - chi
GR  - 2017J01242/Health Joint Project of Fujian Provincial Natural Science Foundation 
      (General program)/
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - B7-H1 Antigen/genetics
MH  - Genes, myc
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large-Cell, Anaplastic/genetics
MH  - Proto-Oncogene Proteins c-myc
MH  - Receptor Protein-Tyrosine Kinases/genetics
EDAT- 2021/06/04 06:00
MHDA- 2021/06/05 06:00
CRDT- 2021/06/03 04:47
PHST- 2021/06/03 04:47 [entrez]
PHST- 2021/06/04 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
AID - 10.3760/cma.j.cn112151-20201223-00953 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2021 Jun 8;50(6):598-603. doi: 
      10.3760/cma.j.cn112151-20201223-00953.